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Abstract Hereditary angioedema due to C1 inhibitor (C1
esterase inhibitor) deficiency (types I and II HAE-C1-INH)
is a rare disease that usually presents during childhood or
adolescence with intermittent episodes of potentially life-
threatening angioedema. Diagnosis as early as possible is
important to avoid ineffective therapies and to properly treat
swelling attacks. At a consensus meeting in June 2011,
pediatricians and dermatologists from Germany, Austria,
and Switzerland reviewed the currently available literature,
including published international consensus recommendations
for HAE therapy across all age groups. Published recommen-
dations cannot be unconditionally adopted for pediatric
patients in German-speaking countries given the current
approval status of HAE drugs. This article provides an over-
view and discusses drugs available for HAE therapy,
their approval status, and study results obtained in adult
and pediatric patients. Recommendations for developing ap-
propriate treatment strategies in the management of HAE in
pediatric patients in German-speaking countries are provided.
Conclusion Currently, plasma-derived C1 inhibitor concentrate
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Introduction
Hereditary angioedema (HAE) is a rare disease that usually
manifests in childhood or adolescence. The pathogenesis is
either related to insufficient levels of functional C1 inhibitor
(C1-INH) (type I HAE) or normal levels of dysfunctional
C1-INH (type II HAE). Patients with type III HAE are mainly
women and have normal levels of functional C1-INH, al-
though some will demonstrate activating mutations in the
coagulation factor XII (Hageman factor; HAE-FXII). Type
III is essentially irrelevant in children and adolescents. For
that reason, this consensus will focus solely on types I and II
HAE.
The characteristic symptoms of HAE include recurrent
spontaneous swellings of the skin and mucosal tissues that
mimic allergic Quincke edema. However, in contrast to
allergic reactions, these swelling sites tend to be pale, hard,
and doughy, sometimes causing considerable tension-
induced pain. The fact that they do not cause itching may
be helpful in an emergency setting to aid the differential
diagnosis in contrast to an allergic reaction. Urticaria
is atypical for C1-INH deficiency, while erythema
marginatum-like erythema has been observed in individual
patients prior to the onset of an attack. Without knowledge
of the underlying disease, abdominal colic caused by swell-
ing attacks in the bowel may give rise to surgical interven-
tion (mostly for appendicitis or mechanical ileus). An
abdominal ultrasound can provide clues as to whether the
typical cocarde reaction occurs in the appendix or whether
HAE-related swelling has caused thickening of the bowel
wall. Swellings in the genital region may also occur, and
laryngeal swelling can be life-threatening. Deaths by as-
phyxiation following laryngeal swelling have been reported
in many families, including a 9 year-old boy who died from a
laryngeal swelling that was the first clinical sign of his C1-INH
deficiency [1–4]. If left untreated, attacks usually occur inter-
mittently and are subject to great interindividual variability
[33]. Classically, the attacks develop slowly over 24 h and
resolve spontaneously without intervention after another 2 to
3d a y s .
The trigger of the attacks cannot always be determined.
Minor injury, dental work, an infection (e.g., Epstein–Barr
virus or Helicobacter pylori), mental stress, or drugs like
angiotensin-converting enzyme inhibitors can all precipitate
an attack. Most contraceptives (apparently not progestin-only
products with pure progestin) and menstruation have been
occasionally identified as triggers.
Unfortunately, it often takes many years until the diag-
nosis of HAE is established. Yet, the earliest possible diag-
nosis can help avoid administration of ineffective therapies
and, in isolated cases, even prevent life-threatening situa-
tions such as laryngeal edema. When an HAE patient has
been identified in a family, it is imperative that the entire
family, including any infants and toddlers, be examined.
Indeed, there is often an autosomal-dominant pattern of
inheritance (see the Online Mendelian Inheritance in Man
database, entry 106100). If the disease can be diagnosed
successfully before patients experience their first severe
swelling attack, effective preventive or therapeutic measures
can be taken.
In 2010, consensus recommendations for therapeutic strat-
egies were issued for all age groups [6] and a pediatric con-
sensus was published in 2005 [7]. In spite of this, the group of
experts (pediatricians and dermatologists) who met in Berlin
on 23 June 2011 to discuss a therapeutic strategy for pediatric
patients that is compatible with the marketing approval status
in these countries were concerned whether the existing inter-
national consensus papers can be unconditionally adopted for
children and adolescents in German-speaking countries due to
both medical and legal issues. The aims of the consensus
meeting were:
1. to present all drugs available for the therapy of HAE and
discuss the study results obtained in adults and children
along with the adverse effects of these forms of therapy.
2. to determine which of these available drugs are approved
in German-speaking countries and integrate them into a
therapeutic strategy for managing HAE in children and
adolescents.
3. to brainstorm how to further improve HAE therapy in
children and adolescents in the future.
The experts at the meeting also intentionally addressed
compounds that are presently approved for adults only be-
cause pediatricians should be able to answer questions
concerning the therapeutic options available to their patients
post-adolescence. Moreover, it is anticipated that further
approvals will be granted for children and adolescents as
soon as the corresponding study results become available.
Experts participating in the consensus meeting unani-
mously agreed that, under all circumstances, the current
1340 Eur J Pediatr (2012) 171:1339–1348drug approvals in the individual countries should be con-
sidered before deciding, in isolated cases, on off-label ad-
ministration of therapeutics that are only approved in other
countries.
Approval status and overview of HAE-C1-INH
therapeutics—current data from clinical studies
in children and adults, including risks
Table 1 presents an overview of the current approval status
of drugs used in the management of HAE. The individual
HAE therapeutics and study results obtained in adults and
children are summarized below; an overview of specific
risks and adverse events for the treatment with the available
drugs is provided in Table 2 and an assessment on use in
pediatrics is provided in Table 3.
The consensus meetingrelatingtochildrenandadolescents
did not consider data from studies in pregnant and nursing
mothers.
Human plasma-derived C1-INH (pdC1-INH) concentrates
Human C1-INH, a single-chain glycoprotein consisting of
478 amino acids with a molecular weight of approximately
105 kDa, is a member of the serine protease inhibitor family
(SERPIN). Its main function is to inhibit the early activation
steps of the complement and kallikrein–kinin systems
(see Fig. 1).
Berinert®
Berinert is derived from human plasma. The risk of virus
transmission is reduced by pasteurization, hydrophobic inter-
action chromatography, and virus filtration (nanofiltration) us-
ingtwofiltersinseries.Thedosingrecommendationis20U/kg
body weight, intravenous. Berinert is approved for treating
acute attacks of HAE in all pediatric age groups (Table 1).
In the randomized, double-blind, placebo-controlled
study I.M.P.A.C.T.1, 124 patients (6 to 72 years of age)
were treated for each attack (abdominal or facial) with 10
or 20 U/kg of Berinert or with placebo [12]. With 20 U/kg
Berinert, the median time to the onset of symptom relief was
significantly shorter compared to placebo (0.50 vs. 1.5 h;
p00.0025), whereas this time was not significantly shorter
compared to placebo in patients receiving 10 U/kg Berinert
( 1 . 2h ) .W i t h2 0U / k gB e r i n e r t ,t h em e d i a nt i m et ot h e
complete resolution of all HAE symptoms was significantly
shorter compared to placebo (4.92 vs. 7.79 h; p00.0237).
In I.M.P.A.C.T.2, an open-label extension study of
I.M.P.A.C.T.1, which investigated long-term therapy with
Berinert, 1,085 attacks at any body location in 57 patients
(10 to 53 years of age) were treated with 20 U/kg of Berinert
[13]. The median time to the onset of symptom relief was
0.46 h and was comparable for attacks at all body locations.
The median time to complete resolution of all symptoms
was 15.5 h (shortest for laryngeal attacks, 5.8 h). In 99 % of
all attacks (1,073 of 1,085), a single dose of 20 U/kg was
sufficient. One 10 year-old child and six adolescents be-
tween 12 and 16 years of age participated in the study;
subgroup analyses indicated that the results were compara-
ble across all age groups. There were no serious adverse
effects, and no neutralizing anti-C1-INH antibodies were
detected.
A retrospective study showed that 500 U of Berinert were
efficacious for short-term prophylaxis [16]. In a study on
short-term prophylaxis with Berinert in adults and children,
swelling attacks occurred in approximately 20 % of 577
tooth extractions performed without short-term prophylaxis,
whereas they occurred in <12 % of the 128 tooth extractions
with short-term prophylaxis [3]. Evidence for effective long-
term prophylaxis with Berinert has been recently published
[14, 31].
In a recently published retrospective study, home therapy
with Berinert was shown to be effective and safe in children
and adolescents [22]. In a pharmacokinetic study in 6 chil-
dren and 34 adults (receiving on-demand treatment or indi-
vidual replacement therapy), the median half-life of C1-INH
activity was 32.9 h in children and 39.1 h (on-demand
therapy) and 30.9 h (individual replacement therapy), re-
spectively, in adult patients [26].
Cinryze®
Cinryze is derived from human plasma. The risk of virus
transmission is reduced by polyethylene glycol precipita-
tion, pasteurization, and virus filtration (nanofiltration) us-
ing two filters in series. The dosing recommendation is
1,000 U (two vials), intravenous, irrespective of the body
weight. Cinryze is also approved in adolescents for treating
acute attacks of HAE, as well as for short-term and long-
term prophylaxis (Table 1).
Two double-blind, randomized, placebo-controlled stud-
ies were conducted, one on the treatment of acute swelling
attacks and another one on long-term prophylaxis [34]. In
both studies, there were no serious adverse effects.
In the acute-treatment study, 71 patients with swelling
attacks involving the face, abdomen, or external genitalia
were treated with 1,000 U of Cinryze or placebo. Patients
not responding within 1 h received a second dose. If the
symptoms did not subside or worsened after 4 h elapsed, the
patients received another dose of 1,000 U (open-label rescue
medication). The median time to onset of unequivocal relief
with Cinryze was 2 h (placebo, 4 h; p00.048). The median
time to the complete resolution of symptoms with Cinryze
was 12.3 h (placebo, 25.0 h; p00.004).
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1342 Eur J Pediatr (2012) 171:1339–1348In the long-term prophylaxis study, 24 patients (from the
acute-treatment study) with at least 2 attacks per month
received 1,000 U of Cinryze or placebo every 3 to 4 days
(crossover after 12 weeks). During the 12 week treatment
period, the number of swelling attacks was significantly
lower with Cinryze compared to placebo (mean, 6.1 vs.
12.7 attacks; p<0.0001).
In an interim analysis of an open-label extension study
(median duration, 11 months), 88 patients had received
Cinryze, some repeatedly, for the treatment of acute attacks,
including laryngeal attacks [34]. The repeated treatment also
proved effective. Data on home therapy with Cinryze have
not been published yet.
In various studies, a total of 46 patients <18 years of age
were treated with Cinryze (2 to 5 years, 3 patients; 6 to
11 years, 17 patients; 12 to 17 years, 26 patients) [11].
Overall, the safety, tolerability, and efficacy of Cinryze were
comparable with those of adults in both acute treatment and
long-term prophylaxis.
Recombinant human C1-INH concentrate (Ruconest®)
The active ingredient of Ruconest, conestat alfa, is a recombi-
nant analogue of human C1-INH (a single-chain glycoprotein
with a molecular weight of 71 kDa). Its glycosylation is not
identical to that of human C1-INH, which is presumably the
reason for its shorter half-life [17]. Ruconest is produced
recombinantly in transgenic New Zealand rabbits and purified
from their milk. The dosing recommendation is 50 U/kg,
intravenous (maximum dose of 4,200 U in patients with body
weight >84 kg, maximum of two doses within of 24 h).
Two randomized, double-blind, placebo-controlled studies
have been conducted for dose finding (100 U/kg vs. placebo
and 50 vs. 100 U/kg vs. placebo) [35]. Relief of symptoms was
similar and significantly faster with 50 and 100 U/kg compared
with placebo. There were no serious adverse effects. To date,
no data have been published on use in children.
Kallikrein inhibitor and bradykinin receptor antagonists
Icatibant (Firazyr®)
Icatibant, a chemically synthesized decapeptide with a
bradykinin-like structure, is a selective antagonist of the bra-
dykinin B2 receptor. Its amino acid sequence makes icatibant
resistant to enzymatic degradation. The dosing recommenda-
tion is 30 mg, subcutaneous (prefilled syringe), with a maxi-
mum of three doses within 24 h.
Table 2 Specific risks and adverse events of products for the treatment of HAE-C1-INH
Active ingredient/trade name Risks and adverse events
Human pdC1-INH concentrates
Berinert® A theoretical risk of pathogen transmission is associated with all plasma products.
No such transmissions have thus far been described. In this respect, the product
can be judged to be safe. It was speculated that long-term use of Berinert may
be associated with an increased frequency of HAE-C1-INH attacks [2].
Cinryze® A theoretical risk of pathogen transmission is associated with all plasma products.
No such transmissions have thus far been described. In this respect,
the product can be judged to be safe.
Recombinant human C1-INH concentrate
Ruconest® Several patients developed antibodies to rabbit antigens (from dander and hair,
not from the C1-INH); allergic reactions were observed rarely.
Kallikrein and bradykinin receptor antagonists
Icatibant/Firazyr® From the theoretical perspective, caution is advised in patients with ischemic heart
disease, unstable angina pectoris, and in the first weeks following a stroke.
Clinically relevant problems in this regard have not been observed to date.
Ecallantide/Kalbitor™ Worth mentioning is the risk of anaphylactic reactions (frequency according to the
boxed warning in the USA full prescribing information, 3.9 % [21]).
Attenuated androgens
Danazol/Danatrol® The most common adverse effects are virilization, weight gain, menstrual irregularities,
depression/aggression, myalgia, and acne. Adverse effects such as hypercholesterolemia,
hypertension, erythrocytosis, and hepatic tumors mandate the need for regular medical
checkups. Furthermore, in children, growth disorders and premature closure of
the epiphyseal cartilage are conceivable and have not been
sufficiently analyzed in clinical studies.
Danazol/Danokrin®
Danazol/Danocrine™
Stanozolol/Winstrol™
Antifibrinolytics
Tranexamic acid/Cyklokapron® The most common adverse effects are dose-dependent gastrointestinal symptoms
(nausea, vomiting, and diarrhea).
Eur J Pediatr (2012) 171:1339–1348 1343In the randomized, double-blind studies FAST-1 (placebo-
controlled) and FAST-2 (tranexamic acid-controlled), 56 and
74adults,respectively,receivedtreatmentwithicatibantorthe
respective comparator for 1 attack [8]. In FAST-1, the median
time to clinically significant improvement was achieved after
2.5hwithicatibant(placebo,4.6h)and,inFAST-2,after2.0h
(tranexamic acid, 12.0 h). No serious adverse effects were
observed. A study in children and adolescents is currently in
the concrete planning stage.
Ecallantide (Kalbitor™)
Ecallantide (DX-88) is a 60-amino-acid recombinant protein
that reversibly inhibits the activity of kallikrein [19] (see
Fig. 1) .T h ed o s i n gr e c o m m e n d a t i o ni s3 × 1 0m gg i v e ns u b -
cutaneously, with a maximum of two doses within 24 h.
Two randomized, double-blind, placebo-controlled studies
for approval in the USAwith a similar study design have been
published on the acute treatment of HAE. In the EDEMA3
study, 71 patients (minimum age, 10 years) were treated with
30 mg ecallantide or placebo for acute attacks [10]. There was
asignificantimprovementintheprimaryendpointofthestudy
(treatment outcome score 4 h after administration) for the
active drug group compared to placebo.
In the EDEMA4 study in 96 patients, the mean symptom
complex severity score and the treatment outcome score
showed a significant improvement after 4 h in the active
drug group compared to placebo [24]. In a combined anal-
ysis of data from EDEMA3 and EDEMA4, the product was
also demonstrated to have good efficacy and good tolerabil-
ity [30]. The most frequent adverse effects were headache,
nausea, fever, diarrhea, nasopharyngitis, or local injection-
site reactions [10, 19, 24, 30].
Attenuated androgens
In many parts of the world, androgen derivatives (meth-
yltestosterone, danazol, stanozolol, and oxandrolone) are
used for short-term and long-term prophylaxis. C1-INH
plasma levels rise with the administration of attenuated
androgens, which provides at least a partial explanation for
their effect.
The approval status differs in German-speaking countries
(see Table 1). For long-term prophylaxis in adolescents,
Table 3 Assessment on pediatric use for the treatment of HAE-C1-INH
Active ingredient/trade name Assessment on pediatric use
Human pdC1-INH concentrates
Berinert® Pediatric data for Berinert indicate that its efficacy and safety of 20 U/kg
in pediatric patients are comparable with that for adults.
Cinryze® Pediatric data for Cinryze indicate that its efficacy, safety, and tolerability
in pediatric patients are comparable with that for adults. The recommended
dose (1,000 U) is the same for all types of attacks and for all body weights.
The paucity of data on body weight-based dosing, as is otherwise common
in pediatrics, is seen as critical. No adverse effects in adults and adolescents
from high doses have become known to date. Cinryze is not yet approved for
the management of acute attacks and for prophylaxis in children.
Recombinant human C1-INH concentrate
Ruconest® Until data on children and adolescents are published and approval of the drug
is granted, Ruconest should only be used when specifically warranted.
Kallikrein inhibitor and bradykinin receptor antagonists
Icatibant/Firazyr® On a preliminary basis, no recommendation favoring use in children and adolescents
can be made, given the lack studies in pediatric patients.
Ecallantide/Kalbitor™ The currently available data on the treatment of pediatric patients is insufficient.
Moreover, no European approval is available.
Attenuated androgens
Danazol/Danatrol® Given their adverse reaction profile, at present, androgens should not be used for
the long-term prophylaxis of pediatric HAE-C1-INH. Neither can a recommendation
be given for short-term prophylaxis, despite the fact that danazol is approved in
Switzerland for children >12 years of age.
Danazol/Danokrin®
Danazol/Danocrine™
Stanozolol/Winstrol™
Antifibrinolytics
Tranexamic acid/Cyklokapron® The use of ε-aminocaproic acid cannot be recommended, as it is approved in some countries
by regulatory authorities for the treatment of HAE. Due to the doubtful efficacy of
tranexamic acid, it should be avoided for short-term and long-term
prophylaxis in pediatric patients.
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informationofthiscountrystatesthatadolescents>12yearsof
age should receive an initial daily dose of 400 to 600 mg and
that the dose should be incrementally reduced down to the
lowest effective dose. Experts explicitly do not recommend
androgen therapy for long-term prophylaxis in children [6, 9,
27]. The dose recommended for short-term prophylaxis is 2.5
to10 mg/kg daily (maximum, 600 mgdaily)for 5 daysbefore
to 2 days after the intervention [6]. The experts at the current
consensus meeting considered this international recommen-
dation as problematic for pediatric patients (see below).
There are no clinical studies in children and adolescents
with HAE. A small case collection provides some data on the
efficacy and tolerability at low doses [15].
Antifibrinolytics
Antifibrinolytics (ε-aminocaproic acid or tranexamic acid
[cyclic analogue of ε-aminocaproic acid]) are chemically
synthesized and exert their action in HAE by inhibiting the
conversion of plasminogen to plasmin (see Fig. 1). Antifi-
brinolytics are less effective than attenuated androgens [6].
The dosing recommendation for tranexamic acid is 20 to
50 mg/kg daily; the lowest effective dose should be aimed
for [6].
Earlier double-blind, placebo-controlled studies on these
compounds (in 5 to 18 patients, only a few children) showed
a reduction in the frequency of attacks [18, 20, 29]. A recent
prospective study comparing long-term prophylaxis in patients
Fig. 1 Mechanisms of action for therapeutic agents in treating or pre-
venting HAE. Multiple pathways are capable of complement activation
and generating inflammatory mediators including complement anaphyla-
toxinsC3a and, more important,C5a.Activation of the finalcomplement
cascade produces a membrane attack complex that produces cellular
injury. Angioedema occur after tissue injury from multiple causes. Tissue
injury can activate contact activation (Hageman factor or factor XII) to
generate kallikrein from prekallikrein, its precursor. Kallikrein in turn
generates and activates plasmin from plasminogen, and plasmin can
directly activate the C1 esterase complex to initiate complement
activation.Undernormalcircumstances,C1-INHfunctionstoinhibitboth
complement activation and, to a lesser extent, modulate contact activa-
tion. In HAE-C1-INH, because of quantitative or qualitative detective
C1-INH, the pathway proceeds unchecked, generating mediators that
increase capillary permeability to produce angioedema. Therapeutic
approaches are directed at acutely restoring C1-INH levels, inhibiting
kallikrein with ecallantide, inhibiting bradykinin with icatibant, and
inhibiting plasmin with the lysine analogue tranexamic acid. Attenuated
androgens have been used to increase liver synthesis of C1-INH. Figure
and description have been adapted from [23]
Eur J Pediatr (2012) 171:1339–1348 1345with and without tranexamic acid did not demonstrate any
effect [32].
Evaluation of recent consensus documents focusing
on the differences between children and adults
Two international consensus papers [6, 25] have issued the
recommendations summarized below for the treatment of acute
attacks, short-term prophylaxis, and long-term prophylaxis.
Acute attacks
Human pdC1-INH is recommended for all attacks (for
adults and children). “Wait and see” is only an option for
attacks not involving the face, neck, or abdomen and intes-
tine.Hometherapyisrecommendedforchildrenwithfrequent
and debilitating attacks, under the condition of medically
supervised training.
For recombinant C1-INH concentrate (Ruconest), these
consensus papers do not give any recommendation whatso-
ever because this drug first became available in Europe for
the treatment of acute attacks in adults in 2010. In an
updated version of the consensus paper from 2010, Bowen
added recombinant C1-INH concentrate (50 U/kg) for the
treatment of acute attacks [5]. To date, there is no experience
on its use in children.
Short-term prophylaxis
In children, pdC1-INH is recommended for short-term pro-
phylaxis. Should pdC1-INH not be available, danazol is also
recommended for children. The indication for short-term
prophylaxis in children is primarily for surgeries performed
in the head and neck area.
Long-term prophylaxis
Theonlytreatmentoptionforlong-termprophylaxisinchildren
is pdC1-INH. Attenuated androgens are not recommended.
Tranexamic acid (less effective than attenuated androgens) is
recommended for long-term prophylaxis in patients for whom
pdC1-INH is not available or in whom attenuated androgens
are deemed unacceptable.
At the current pediatric consensus meeting for German-
speaking countries, several concerns were raised about these
international consensus recommendations:
& Experts strongly advocated taking body weight into
account in treatment in pediatrics. Discomfort emerged
as to whether appropriate dosing is possible for patients
between 12 and 18 years of age with fixed doses estab-
lished in adults.
& For attenuated androgens, sufficient data are lacking on
the long-term safety over decades of use and, addition-
ally, on the growth rate and bone maturation during the
growth phase. Should there be a reason for its use in
isolated cases, the initial dose (see above) should only be
administered for a short period (e.g., for short-term
prophylaxis prior to elective procedures). Since approval
for children is lacking for long-term use, the issue of
dosing will not be addressed further.
& The data available on the efficacy of tranexamic acid are
considered insufficient, and therefore, its use cannot be
recommended on principle.
Conclusion
Taking into account the approval status (Table 1) and the
published data, the participants at the consensus meeting
Table 4 Consensus on the treatment of children and adolescents with types I and II HAE-C1-INH
Therapy for acute attacks Short-term and
long-term prophylaxis
Peripheral and urogenital Abdominal Facial and laryngeal
“Wait and see” +/− +/−− n/a
pdC1-INH concentrate + + + +
a
Recombinant C1-INH concentrate,
Icatibant and Ecallantide
b,c
−− − −
Attenuated androgens
d −− − −
Tranexamic acid −− − −
n/a not applicable, +/− depending on the intensity
aOf the two available products, only Cinryze is approved for long-term prophylaxis
bRecombinant C1-INH concentrate, ecallantide, and icatibant are currently not approved for children and adolescents in Europe. Studies in children
and adolescents are required
cNo approval for ecallantide in Europe
dAttenuated androgens are not approved in Germany, in Austria not for children
1346 Eur J Pediatr (2012) 171:1339–1348reached the conclusions summarized in Table 4 regarding
recommendations for products for use in children and
adolescents.
In some situations, a “wait and see” strategy may be uti-
lized, depending on the location and intensity of the attack.
This optionmay beconsideredif theswelling is not too painful
and does not impair the patient’s everyday activities and must
be mutually agreed upon between the treating physician and
the patient. Attacks thatare painfulor cause any impairmentto
the patient’s everyday activities should always be treated.
With all products indicated for the treatment of acute
attacks, a further dose should be given whenever the patient
failstonoticeablyrespondtothetreatmentwithin2to3h(i.e.,
if the swelling continues to get worse).
Home therapy with pdC1-INH is possible for accordingly
instructed and educated patients (or their parents or guardians).
A home therapy regimen is particularly reasonable when long-
term prophylaxis is necessary; although the frequency of
attacks (one per week?, two per week?) appropriate for this
therapeuticoptionstillneedstobedefined.Aformalconsensus
on this was not issued, seeing as this indication is very rare in
childhood, because the overwhelming majority of pediatric
patients have markedly fewer attacks. While not an evidence-
based guideline, the consensus that was reached nevertheless
fosters clear-cut decisions for treatment strategies.
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